Search Weight Loss Topics:

Page 41«..1020..40414243..»

Home » Hgh » Page 41

August 14, 2017 - By Marguerite Chambers

Among 13 analysts covering Cineworld Group PLC (LON:CINE), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. Cineworld Group PLC had 131 analyst reports since July 24, 2015 according to SRatingsIntel. As per Thursday, March 9, the company rating was maintained by N+1 Singer. Barclays Capital maintained Cineworld Group plc (LON:CINE) on Monday, July 11 with Overweight rating. The company was maintained on Tuesday, August 4 by Numis Securities. HSBC maintained Cineworld Group plc (LON:CINE) rating on Tuesday, April 4. HSBC has Buy rating and GBX 750 target. As per Friday, October 9, the company rating was maintained by Canaccord Genuity. On Thursday, January 7 the stock rating was maintained by Numis Securities with Add. On Friday, July 29 the stock rating was maintained by JP Morgan with Overweight. The rating was maintained by Investec on Thursday, August 13 with Buy. The stock of Cineworld Group plc (LON:CINE) earned Overweight rating by J.P. Morgan on Friday, September 25. J.P. Morgan maintained Cineworld Group plc (LON:CINE) on Monday, November 2 with Overweight rating. See Cineworld Group plc (LON:CINE) latest ratings:

10/08/2017 Broker: Canaccord Genuity Rating: Hold Old Target: GBX 630.00 New Target: GBX 700.00 Reiteration10/08/2017 Broker: Investec Rating: Buy New Target: GBX 825.00 Maintain10/08/2017 Broker: N+1 Singer Rating: Buy Old Target: GBX 760.00 New Target: GBX 770.00 Upgrade10/08/2017 Broker: Numis Securities Rating: Hold Old Target: GBX 750.00 New Target: GBX 750.00 Maintain10/08/2017 Broker: Peel Hunt Rating: Add Old Target: GBX 775.00 New Target: GBX 775.00 Maintain26/07/2017 Broker: Berenberg Rating: Buy Old Target: GBX 675.00 New Target: GBX 800.00 Reiteration25/07/2017 Broker: Numis Securities Rating: Hold Old Target: GBX 750.00 New Target: GBX 750.00 Maintain11/07/2017 Broker: Deutsche Bank Rating: Buy Old Target: GBX 825.00 New Target: GBX 825.00 Maintain15/06/2017 Broker: Investec Rating: Buy New Target: GBX 825.00 Maintain09/06/2017 Broker: Peel Hunt Rating: Add Old Target: GBX 775.00 New Target: GBX 775.00 Maintain

Barings Global Short Duratin Hgh Yld Fnd (BGH) formed multiple top with $20.78 target or 3.00% above todays $20.17 share price. Barings Global Short Duratin Hgh Yld Fnd (BGH) has $404.57M valuation. The stock increased 0.95% or $0.19 on August 11, reaching $20.17. About shares traded. Barings Global Short Duratin Hgh Yld Fnd (NYSE:BGH) has risen 16.94% since August 14, 2016 and is uptrending. It has outperformed by 0.24% the S&P500.

About 74,303 shares traded. Cineworld Group plc (LON:CINE) has 0.00% since August 14, 2016 and is . It has underperformed by 16.70% the S&P500.

Cineworld Group plc is a United Kingdom international cinema chain. The company has market cap of 1.96 billion GBP. The Firm operates in approximately nine countries. It has a 20.08 P/E ratio. The Firm operates through two divisions: UK and Ireland, and Central and Eastern Europe and Israel .

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Continue reading here:
Barings Global Short Duratin Hgh Yld Fnd (BGH) At $20.17 Forms Top; Cineworld Group plc (LON:CINE) Had 11 ... - High Point Observer

Click on our two main links above to start shopping for either HGH or IGF-1 or HERE TO BUY HYGETROPIN and HERE TO BUY TURBO VITAL.

We are the official reseller of http://www.hygetropin.cn and we sell only products from the Hygene BioPharm lab. Those products are HGH ( Somatropin 191aa ) and IGF-1 ( Long R3 ) . You can verify that we are the only official reseller of this products by going to http://www.hygetropin.cn.

We accept payment by Western Union / MoneyGram, International Bank transfer and Bitcoin.

IMPORTANT : Hygetropin is the most copied / faked brand of Human Growth Hormone. New copycat / scam website pop up every day stating they are selling what we sell. Please educate yourself before buying a product such as Human Growth Hormone online.

For a full list of Hygetropin scam sites go to http://www.hygetropin.cn

To verify http://www.hygetropin.cn is the original site ( established 2006 ) please look here http://who.is/hygetropin.cn

The vision we had when creating this site was to only stock products that we could stand behind fully. We have a direct relationship with the lead scientist that helped create the stable 191 amino acid sequence Somatropin at Gensci Jintropin ; Dr. Jei Lin. Click here to read more about Dr. Lin. The products we sell have one thing in common. They were all created by Dr. Lin and he is still directly or indirectly connected with each product.

To see that we've been around for a while, please look athttp://who.is/whois/shop-hgh.com.

If you have been with us for a while and want to submit your lab results, please contact us. We want to create another section of this website where we show lab results over time.

Thank you

See the original post here:
Buy Hygetropin HGH by Hygene Biopharm | Shop-HGH - The ...

Published: May, 2010

In 1513, the Spanish explorer Juan Ponce de Len arrived in Florida to search for the fountain of youth. If he got any benefit from his quest, it was due to the exercise involved in the search.

Few men today believe in miraculous waters, but many, it seems, believe in the syringe of youth. Instead of drinking rejuvenating waters, they inject human growth hormone to slow the tick of the clock. Some are motivated by the claims of the "anti-aging" movement, others by the examples of young athletes seeking a competitive edge. Like Ponce de Len, the athletes still get the benefit of exercise, while older men may use growth hormone shots as a substitute for working out. But will growth hormone boost performance or slow aging? And is it safe?

Growth hormone (GH) is a small protein that is made by the pituitary gland and secreted into the bloodstream. GH production is controlled by a complex set of hormones produced in the hypothalamus of the brain and in the intestinal tract and pancreas.

The pituitary puts out GH in bursts; levels rise following exercise, trauma, and sleep. Under normal conditions, more GH is produced at night than during the day. This physiology is complex, but at a minimum, it tells us that sporadic blood tests to measure GH levels are meaningless since high and low levels alternate throughout the day. But scientists who carefully measure overall GH production report that it rises during childhood, peaks during puberty, and declines from middle age onward.

GH acts on many tissues throughout the body. In children and adolescents, it stimulates the growth of bone and cartilage. In people of all ages, GH boosts protein production, promotes the utilization of fat, interferes with the action of insulin, and raises blood sugar levels. GH also raises levels of insulin-like growth factor-1 (IGF-1).

GH is available as a prescription drug that is administered by injection. GH is indicated for children with GH deficiency and others with very short stature. It is also approved to treat adult GH deficiency an uncommon condition that almost always develops in conjunction with major problems afflicting the hypothalamus, pituitary gland, or both. The diagnosis of adult GH deficiency depends on special tests that stimulate GH production; simple blood tests are useless at best, misleading at worst.

Adults with bona fide GH deficiencies benefit from GH injections. They enjoy protection from fractures, increased muscle mass, improved exercise capacity and energy, and a reduced risk of future heart disease. But there is a price to pay. Up to 30% of patients experience side effects that include fluid retention, joint and muscle pain, carpal tunnel syndrome (pressure on the nerve in the wrist causing hand pain and numbness), and high blood sugar levels.

Adults who are GH deficient get larger muscles, more energy, and improved exercise capacity from replacement therapy. Athletes work hard to build their muscles and enhance performance. Some also turn to GH.

It's not an isolated problem. Despite being banned by the International Olympic Committee, Major League Baseball, the National Football League, and the World Anti-Doping Agency, GH abuse has tainted many sports, including baseball, cycling, and track and field. Competitive athletes who abuse GH risk disqualification and disgrace. What do they gain in return? And do they also risk their health?

Because GH use is banned and athletic performance depends on so many physical, psychological, and competitive factors, scientists have been unable to evaluate GH on the field. But they can conduct randomized clinical trials that administer GH or a placebo to healthy young athletes and then measure body composition, strength, and exercise capacity in the lab.

A team of researchers from California conducted a detailed review of 44 high-quality studies of growth hormone in athletes. The subjects were young (average age 27), lean (average body mass index 24), and physically fit; 85% were male. A total of 303 volunteers received GH injections, while 137 received placebo.

After receiving daily injections for an average of 20 days, the subjects who received GH increased their lean body mass (which reflects muscle mass but can also include fluid mass) by an average of 4.6 pounds. That's a big gain but it did not translate into improved performance. In fact, GH did not produce measurable increases in either strength or exercise capacity. And the subjects who got GH were more likely to retain fluid and experience fatigue than were the volunteers who got the placebo.

If you were a jock in high school or college, you're likely to wince at the memory of your coach barking "no pain, no gain" to spur you on. Today, athletes who use illegal performance-enhancing drugs risk the pain of disqualification without proof of gain.

Among its many biological effects, GH promotes an increase in muscle mass and a decrease in body fat. As men age, GH levels fall. During the same time span, muscle mass declines and body fat increases. And so, the theory goes, the way to arrest these effects of aging is to inject GH.

Similar claims have been made for other hormones that decline with age, including testosterone and dehydroepiandrosterone (DHEA) in men, and estrogen in women. Research shows that estrogen replacement does more harm than good in older women, and there is no solid evidence that testosterone and DHEA are safe and effective for healthy older men. But that has not stopped the growth of "anti-aging" and "regenerative medicine" clinics and Web sites.

Expensive injections of growth hormone are offered by many practitioners, even though the FDA has not approved the use of GH for anti-aging, body building, or athletic enhancement, and the marketing or distribution of the hormone for any of these purposes is illegal in the U.S. According to one estimate, 20,000 to 30,000 Americans used GH as "anti-aging" therapy in 2004 alone; according to another, 100,000 people received GH without a valid prescription in 2002.

To evaluate the safety and efficacy of GH in healthy older people, a team of researchers reviewed 31 high-quality studies that were completed after 1989. Each of the studies was small, but together they evaluated 220 subjects who received GH and 227 control subjects who did not get the hormone. Two-thirds of the subjects were men; their average age was 69, and the typical volunteer was overweight but not obese.

The dosage of GH varied considerably, and the duration of therapy ranged from two to 52 weeks. Still, the varying doses succeeded in boosting levels of IGF-1, which reflects the level of GH, by 88%.

As compared to the subjects who did not get GH, the treated individuals gained an average of 4.6 pounds of lean body mass, and they shed a similar amount of body fat. There was a slight drop in total cholesterol levels, but no significant changes in LDL ("bad") cholesterol, HDL ("good") cholesterol, triglycerides, aerobic capacity, bone density, or fasting blood sugar and insulin levels. But GH recipients experienced a high rate of side effects, including fluid retention, joint pain, breast enlargement, and carpal tunnel syndrome. The studies were too short to detect any change in the risk of cancer, but other research suggests an increased risk of cancer in general and prostate cancer in particular.

"Every man desires to live long," wrote Jonathan Swift, "but no man would be old." He was right, but the fountain of youth has proved illusory. And while more study is needed, GH does not appear to be either safe or effective for young athletes or healthy older men. But that doesn't mean you have to sit back and let Father Time peck away at you. Instead, use the time-tested combination of diet and exercise. Aim for a moderate protein intake of about .36 grams per pound of body weight; even big men don't need more than 65 grams (about 2 ounces) a day, though athletes and men recovering from illnesses or surgery might do well with about 20% more. Plan a balanced exercise regimen; aim for at least 30 minutes of moderate exercise, such as walking, a day, and be sure to add strength training two to three times a week to build muscle mass and strength. You'll reduce your risk of many chronic illnesses, enhance your vigor and enjoyment of life, and it's true slow the tick of the clock.

Link:
Human growth hormone (hGH) - health.harvard.edu

"It was the best of times, it was the worst of times..."

Charles Dickens wasn't referring to Exact Sciences (NASDAQ:EXAS) and Opko Health (NASDAQ:OPK) when he wrote those words, but they're certainly applicable for the two healthcare stocks. 2017 has been a great year so far for Exact Sciences. Shares of the molecular-diagnostics company have soared nearly 180% year to date. But it's a much different story for Opko Health, with its stock plunging more than 30% so far this year.

But is Exact Sciences still the better pick -- or will the tale of two healthcare stocks end up with Opko on top over the long run? Here's how Exact Sciences and Opko Health compare.

Image source: Getty Images.

If you're looking for a good reason to buy Exact Sciences stock, look no further than Cologuard. The company'sDNA screening test for colorectal cancer has arguably experienced the strongest launch of any genetic test in its first three years on the market. Increasingly more providers are prescribing Cologuard, and more payers are loosening their purse strings for reimbursement of the test as well.

The opportunity for future sales growth is significant. There are around 80 million patients who should be tested for colorectal cancer. Many of them don't, however, because of the inconvenience of preparing for and undergoing a colonoscopy. Cologuard's primary draw is that it's easy to use. It's also highly accurate.

Exact Sciences thinks it will be able to eventually capture 30% of the colorectal cancer screening market thanks to the benefits Cologuard offers. That translates to around $4 billion in potential annual revenue. Exact Sciences is on pace to bring in at least $230 million in 2017, which shows just how much growth could be in store if the company is successful in achieving its goal.

There's more to like about Exact Sciences than just Cologuard, though. The company is also working with the Mayo Clinic to develop liquid biopsy technology to detect multiple types of cancer. Exact Sciences is focusing the heaviest right now on early detection of lung cancer. Its effort to expand beyond colorectal cancer screening presents another great reason to like this stock over the long run.

While things aren't going as well right now for Opko Health, the company also has significant potential. Opko focuses on two primary areas: diagnostics and pharmaceuticals.

Opko's diagnostics business segment generates the most revenue currently. Its BioReference Laboratories ranks as the third-largest clinical laboratory with a core genetic testing business in the U.S. Opko also markets a diagnostic test -- 4Kscore prostate cancer test. The company is also developing an immunoassay platform that allows blood tests to be performed quickly and easily in physicians' offices.

Pharmaceuticals, however, could be Opko's greatest growth opportunity. The company has two FDA-approved products on the market. Rayaldee treatssecondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. Varubi treatschemotherapy-induced nausea and vomiting. Rayaldee is more important to Opko's success, however, because the company licensed Varubi to Tesaro in 2010.

The company also has several pipeline candidates that could be winners down the road, two of which are in late-stage clinical studies. Fermagate is being evaluated in a phase 3 study for treating hyperphosphatemia in CKD patients. Long-acting human growth hormone product hGH-CTP is also being evaluated in a phase 3 study for treating pediatric patients.

I think the better pick between these two stocks is Exact Sciences. Opko has potential, but it also faces plenty of significant risks with its pipeline candidates. That's especially true for hGH-CTP. Opko reported disappointing results from a late-stage study of the growth hormone in adults, although the company is still pursuing a path forward for possible regulatory approval.

Exact Sciences also faces some risks. Cologuard might not be as successful as the company hopes. Others could beat Exact Sciences in the race to develop liquid biopsies for early cancer detection. Still, though, I like the odds for Exact Sciences. The best of times for this stock could be in the future.

Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

View post:
The case for Exact Sciences - Motley Fool

Hartford Financial Services Group Inc (HGH)shares are on close watch heading into the middle of the week as the price has moved belowthe Balance Step indicator, revealing a potential near-term bearishtrend. The Balance Step formula is based on near-term moving averages to predict which direction a trend is heading.

When it comes to equity investing, being too confident may be just as detrimental as not being confident enough. Many investors may think they are making all the right moves when the markets are riding high. This may be the case, but sometimes it might be good fortune. Finding confidence to make trades in down market environments may make the difference between a good portfolio and a great portfolio. It can also be quite easy to confuse skill with a long-term bull market. Many bad decisions may still get rewarded when the market keeps heading higher. On the other end of the spectrum, having too much self-doubt may leave an investor with way too many what ifs. Managing confidence in the markets may play a pivotal role when making tough investing decisions. Finding that perfect balance between the needed gusto and the correct amount of caution may help ease the burden moving forward in the equity market.

Investors and traders using technical analysis to examine stocks may be interested in taking a look at the ATR or Average True Range in addition to the Balance Step. Currently, Hartford Financial Services Group Inc (HGH) has a 14-day ATR of 0.30. The Average True Range is an investor tool used to measure stock volatility. The ATR is not used to figure out price direction, just to measure volatility. The ATR is an indicator developed by J. Welles Wilder. Wilder has developed multiple indicators that are still quite popular in todays investing landscape. The general interpretation of the ATR is the higher the ATR value, the higher the volatility.

The Williams Percent Range or Williams %R is another technical indicator worth checking out. Hartford Financial Services Group Inc (HGH) currently has a 14 day Williams %R of -97.94. The Williams %R fluctuates between 0 and -100 measuring whether a security is overbought or oversold. The Williams %R is similar to the Stochastic Oscillator except it is plotted upside-down. Levels above -20 may indicate the stock may be considered is overbought. If the indicator travels under -80, this may signal that the stock is oversold. Chart analysts may also use the indicator to project possible price reversals and to define trends.

The Average Directional Index or ADX is technical analysis indicator used to discern if a market is trending or not trending. The ADX alone measures trend strength but not direction. Using the ADX with the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) may help determine the direction of the trend as well as the overall momentum. Many traders will use the ADX alongside other indicators in order to help spot proper trading entry/exit points. Currently, the 14-day ADX for Hartford Financial Services Group Inc (HGH) is 19.07. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would signal a very strong trend, and a value of 75-100 would indicate an extremely strong trend.

Traders may be leaning on technical stock analysis to help with investing decisions. Hartford Financial Services Group Inc (HGH) currently has a 14-day Commodity Channel Index (CCI) of -104.27. Despite the name, CCI can be used on other investment tools such as stocks. The CCI was designed to typically stay within the reading of -100 to +100. Traders may use the indicator to determine stock trends or to identify overbought/oversold conditions. A CCI reading above +100 would imply that the stock is overbought and possibly ready for a correction. On the other hand, a reading of -100 would imply that the stock is oversold and possibly set for a rally.

Traders are paying renewed attention to shares of Hartford Financial Services Group Inc (HGH). The current 14-day RSI is presently sitting at 38.04, the 7-day is 32.01, and the 3-day is 21.19. The RSI, or Relative Strength Index is a popular oscillating indicator among traders and investors. The RSI operates in a range-bound area with values between 0 and 100. When the RSI line moves up, the stock may be experiencing strength. The opposite is the case when the RSI line is heading lower. Different time periods may be used when using the RSI indicator. The RSI may be more volatile using a shorter period of time. Many traders keep an eye on the 30 and 70 marks on the RSI scale. A move above 70 is widely considered to show the stock as overbought, and a move below 30 would indicate that the stock may be oversold. Traders may use these levels to help identify stock price reversals.

Read the rest here:
What Do The Technicals Boil Down To For Hartford Financial Services Group Inc (HGH)? - Stock Press Daily

August 9, 2017August 9, 2017 EBU Staff Writer

Hartford Financial Services Group Inc (HGH) has a current 14-day RSI of 36.08, the 7-day is 28.61, and the 3-day is resting at 15.53. The RSI, or Relative Strength Index is a widely used oscillating indicator among traders and investors. The RSI operates in a range-bound territory with values between 0 and 100. When the RSI line heads up, the stock may be showing strength. The opposite is the case when the RSI line is moving lower. Alternate time periods may be used when following the RSI indicator. The RSI may be more volatile using a shorter period of time. Many traders keep an eye on the 30 and 70 marks on the RSI scale. A move above 70 is widely considered to show the stock as overbought, and a move below 30 would indicate that the stock may be oversold. Traders may use these levels to help identify stock price reversals.

Traders may be focusing on other technical indicators for stock assessment. Presently, Hartford Financial Services Group Inc (HGH) has a 14-day Commodity Channel Index (CCI) of -123.19. The CCI technical indicator can be used to help determine if a stock is overbought or oversold. CCI may also be used to help discover divergences that could possibly signal reversal moves. A CCI closer to +100 may provide an overbought signal, and a CCI near -100 may offer an oversold signal. Investors may be watching other technical indicators such as the Williams Percent Range or Williams %R. The Williams %R is a momentum indicator that helps measure oversold and overbought levels. This indicator compares the closing price of a stock in relation to the highs and lows over a certain time period.

A common look back period is 14 days. Hartford Financial Services Group Inc (HGH)s Williams %R presently stands at -99.06. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would indicate an overbought situation. A reading from -80 to -100 would indicate an oversold situation.

Currently, the 14-day ADX for Hartford Financial Services Group Inc (HGH) is sitting at 19.55. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would identify a very strong trend, and a value of 75-100 would lead to an extremely strong trend. ADX is used to gauge trend strength but not trend direction. Traders often add the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of a trend.

A widely used tool among technical stock analysts is the moving average. Moving averages are considered to be lagging indicators that simply take the average price of a stock over a certain period of time. Moving averages can be very helpful for spotting peaks and troughs. They may also be used to help the trader figure out reliable support and resistance levels for the stock. Currently, the 200-day MA is sitting at 30.69.

Investors may be trying to decide if stocks will make new highs before the year is out, and whether or not the bull market will celebrate its 9th anniversary next year. The tricky part is prognosticating the short term picture. Investors may not be comfortable enough to go all in, but they may not want to get bearish given the solid economic backdrop. Will there be a big breakout given the strength of earnings and economic growth? Will investors just become numb to the headlines and decide to focus on the positive economic picture? It is always wise to remember that the market can have a correction at any time for any reason. If the political landscape gets even more dysfunctional, then it may be enough of a driver to spur a correction.

See the original post:
Crunching the Numbers for Hartford Financial Services Group Inc (HGH) - The Business Union

This is probably one of the hard bits for most people to follow, because it takes discipline. Fasting. But what I can tell you is that fasting does do a lot to improve the HGH output of your body, as well as contributing to your overall longevity.

Food deprivation has been shown to increase the lifespan of mice in lab conditions, as it is. Back in the old days, food shortages were a normal thing. Today, people eat a lot more. Which isnt really a bad thing. You will notice the human race has increased in size overall, ever since the good old 70s. Its one of the reasons why todays movies set in ancient times are really unrepresentative of the overall height and sizes of people back then.

Dont believe me? Take a look at old pictures of say pre-Depression era pictures of the people back then. Or even any 19th century pics if you can find them online. Back then, if you were 6 feet, you were already a giant of sorts.

But the problem is, our bodies have not been conditioned to be eating all the time. Agriculture only came around about 10,000 years ago. The refrigerator only appeared early this century. We might be bigger, but not necessarily healthier. What then about increases in ailments like osteoporosis, cancer, heart disease, and diabetes? But thats besides the point, even though obesity due to overeating is a major cause of todays ailments.

Eating too much, too often, leads to lowered HGH levels simply because of the increase in insulin required to convert all that blood sugar into proper glycogen stores. Although Ill talk about this in future again, suffice to say, that insulin and HGH dont quite get along. When one is up, the other is down.

When you fast, your body has no reason to produce insulin, therefore it is primed to produce growth hormone. In other words, low insulin levels make for a conducive environment for HGH to be released. Fasting is a very effective means of increasing HGH levels.

But of course fasting also:

Our foods contain a lot of toxins, preservatives, pesticides and other unwanted stuff. These external ingredients accumulate within the body over time. A good fasting program done regularly, should help the body loosen and flush them away.

It may well be that the raise in HGH levels due to controlled food deprivation is what enables the body to actually live a longer lifespan. So, go ahead and try controlled fasting from time to time. If possible, combine that with meditation. Your body and mind will thank you for it.

Go here to read the rest:
Fasting and HGH HGH Talk

A recent study published in the journal Mechanisms of Aging and Development confirms the "anti-aging" effect of high-intensity training.

Telomere shortening occurs as you age, however the factors involved are not entirely understood as of yet. The study was conducted to determine whether age-associated telomere shortening is related to habitual endurance exercise and maximal aerobic capacity.

The results suggest there's a direct association between reduced telomere shortening in your later years and high-intensity-type exercises.

The authors' state:

"The results of the present study provide evidence that leukocyte telomere length (LTL) is related to regular vigorous aerobic exercise and maximal aerobic exercise capacity with aging in healthy humans.

LTL is not influenced by aerobic exercise status among young subjects, presumably because TL is intact (i.e., already normal) in sedentary healthy young adults.

However, as LTL shortens with aging it appears that maintenance of aerobic fitness, produced by chronic strenuous exercise and reflected by higher VO2max, acts to preserve LTL.

Our results indicate that leukocyte telomere length (LTL) is preserved in healthy older adults who perform vigorous aerobic exercise and is positively related to maximal aerobic exercise capacity. This may represent a novel molecular mechanism underlying the "anti-aging" effects of maintaining high aerobic fitness."

But that's not all.

High-intensity interval-type training also boosts human growth hormone (HGH) production. A 2003 study published in the journal Sports Medicine found that "exercise intensity above lactate threshold and for a minimum of 10 minutes appears to elicit the greatest stimulus to the secretion of HGH."

Read the original:
Sprint 8 Exercises Increase Your "Fitness Hormone" Levels

MIAMI, Aug. 08, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO or the Company), reports business and financial results for the three and six months ended June 30, 2017.

Business Highlights

Sales force expansion for RAYALDEE underway. OPKO has made substantial progress in obtaining formulary access for RAYALDEE, with more than 68% of potential patient lives now covered under insurance plans. With the more extensive insurance coverage available, OPKO is continuing to expand its field-based sales force to 70 representatives from the original 35. Phase 2a trial for intravenously administered Factor VII-CTP and Phase 1 trial for subcutaneously administered Factor VII-CTP ongoing. These long-acting forms of Factor VII utilizing OPKOs CTP technology are expected to better support prophylaxis, provide easier administration and decrease dosing frequency for hemophilia patients. Enrollment for global pediatric Phase 3 hGH-CTP clinical trial continues and a Japanese pediatric registration trial for hGH-CTP is now underway.Clinical trials of Claros point-of-care (POC) prostate specific antigen (PSA) test completed and Premarket Approval (PMA) filing anticipated this fall. Analytic and clinical validation studies of OPKOs proprietary POC diagnostic test for PSA have been completed; PMA application to the FDA is planned for 4Q 2017. OPKO expects to begin an additional multicenter study of its POC testosterone test in late 2017 or early 2018, followed by a 510(k) submission to FDA. Initiation of five Phase 2 clinical trials anticipated in 2H 2017 and early 2018.

BioReference Laboratories is well positioned to accelerate revenue growth and expand operating margins through the second half of 2017 and 2018.

Financial Highlights

Conference Call and Webcast Information

OPKOs senior management will provide a business update and discuss results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time today. The conference call dial in information is listed below. To access the webcast, please log on to the OPKO website at http://www.opko.com.

WHEN: Tuesday, August 8, 2017, 4:30 p.m. Eastern time.DOMESTIC DIAL-IN: (866) 634-2258 INTERNATIONAL DIAL-IN: (330) 863-3454PASSCODE: 65755948WEBCAST: http://investor.opko.com/events.cfm

For those unable to participate in the live conference call or webcast, a replay will be available beginning August 8, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 65755948. The replay can be accessed for a period of time on OPKOs website at http://investor.opko.com/events.cfm.

About OPKO Health, Inc.

OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and OPK88004, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia in phase 2a. We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at http://www.opko.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding the market for and sales of our products, whether 4Kscore test utilization will continue to grow, our product development efforts and the expected benefits of our products, including whether our ongoing and future clinical trials will be successfully completed on a timely basis or at all and whether the data from any of our trials will support submission or approval, validation and/or reimbursement for our products, the expected timing for launch of our products in development, whether the data for hGH-CTP will support approval of a BLA, the expected timing of commencing and concluding our clinical trials, enrollment in clinical trials, and disclosure of results for the trials, the timing of our regulatory submissions, our ability to market and sell any of our products in development, expectations about developing RAYALDEE for dialysis patients, our ability to obtain broad reimbursement coverage for the 4Kscore test, expectations regarding revenue growth and operating margins for BioReference for the remainder of 2017 and 2018, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission, as well as integration challenges for Bio-Reference, EirGen, Transition, and other acquired businesses, the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results, that the 4Kscore, RAYALDEE, Varubi, hGH-CTP, OPKO88003, OPK88004, and/or any of our compounds or diagnostic products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications, that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

CompanyOPKO Health, Inc.David Malina, 305-575-4100Investor Relationsdmalina@opko.com

LHAAnne Marie Fields, 212-838-3777afields@lhai.comorBruce Voss, 310-691-7100bvoss@lhai.com

Tables to Follow

OPKO Health, Inc. and SubsidiariesCondensed Consolidated Balance Sheets(unaudited)(in millions)

View post:
OPKO Health Reports Second Quarter 2017 Business and Financial Results - GlobeNewswire (press release)

Trading was light with 24K shares changing hands by the end of trading on Friday. Volume was down 58.05% under the stocks average daily volume.

In the market the company is trading unchanged by 0.42% percent from yesterdays close. Company chares are trading at $30.86 which is just under $31.22, the stocks 50 day moving average and which is slightly below the 200 day moving average of $30.98. The 50 day moving average went down $-0.36 or -1.16% and the 200 day average moved down $-0.12.

The Hartford Financial Services Group, Inc., launched on December 9, 1985, is a holding company for insurance and financial services subsidiaries. The Company, through its subsidiaries, provides property and casualty insurance, group life and disability products, and mutual funds and exchange-traded products to individual and business customers in the United States. The Businesss segments include Commercial Lines, Personal Lines, Property & Casualty Other Operations, Group Benefits, Mutual Funds, Talcott Resolution and Corporate. The Company administers life insurance and annuity products previously sold..

Read more from the original source:
Hartford Financial Services Gro (NYSE:HGH) Experiences Lighter than Average Trading Volume - First News 24

Page 41«..1020..40414243..»

Home » Hgh » Page 41